Lifeward Ltd. Reports Impressive Third Quarter Financial Performance
Leading the way in innovative medical technology, Lifeward Ltd. (Nasdaq: LFWD) is excited to announce its latest financial results for the third quarter. This recent reporting period has been noteworthy for Lifeward as it recorded significant achievements and strategic advancements. From increasing Medicare beneficiary placements to optimizing operational processes, the company is demonstrating a firm commitment to driving positive change for individuals with physical limitations.
Record Medicare Placements and Operational Efficiencies
During this quarter, Lifeward has seen a historic second consecutive record in placements of the ReWalk systems for Medicare beneficiaries. This achievement highlights the company’s focus on aligning its offerings with the needs of patients receiving Medicare. Improved operational efficiencies have contributed to a remarkable 16% year-over-year reduction in cash burn, reflecting diligent fiscal management and strategic decision-making.
Financial Highlights from Q3
In terms of financial performance, Lifeward reported a revenue of $6.2 million for Q3 2025, a slight increase from $6.1 million during the same period last year. This growth trajectory also marks an 8% increase from the previous quarter's revenue of $5.7 million.
Sales from Lifeward’s flagship products, including the ReWalk personal exoskeletons and the MyoCycle FES bike, amounted to $3.1 million—a substantial 24% increase over the prior year. While revenue from the AlterG products experienced a decline to $3.1 million, mainly due to timing variations in sales, the overall performance reflects strong market positioning and customer preference.
Improving Gross Margins
Gross margins for the third quarter of 2025 rose to 43.7%, compared to 36.2% in 2024. This notable increase underscores the company’s success in reducing production costs, particularly following the strategic closure of the Fremont, California manufacturing facility. This step has allowed Lifeward to refine its production processes, which is expected to positively impact margins moving forward.
Financial Guidance and Liquidity Position
Looking ahead, Lifeward maintains a robust liquidity position with $2.0 million in unrestricted cash as of September 30, 2025, and no debt obligations. The company has entered a loan agreement with Oramed Ltd. for $3.0 million, aimed at bolstering financial stability and supporting ongoing operations.
In alignment with its strategic objectives, Lifeward is reaffirming its full-year 2025 financial guidance, projecting revenues between $24 to $26 million, along with a non-GAAP net loss expected between $12 to $14 million. These projections reflect the company’s mission to enhance its operational and financial performance continually.
Vision for the Future
Mark Grant, the President and Chief Executive Officer of Lifeward Ltd., elaborated on the company’s vision, emphasizing that the sequential growth in Medicare placements and enhanced operational efficiency are foundational blocks for the company’s ongoing transformation. Grant noted that the recent CE Mark approval for the ReWalk 7 Personal Exoskeleton further enhances its market potential in Europe, which constitutes a significant portion of Lifeward’s sales.
Conference Call Information
For investors and interested stakeholders, Lifeward management will host a conference call to discuss these results and the company’s strategic commitments in detail. The opportunity for real-time engagement allows for further dialogue on the initiatives propelling growth, market expansion, and product innovation.
Frequently Asked Questions
What were Lifeward's total revenues in the third quarter?
Lifeward reported revenues of $6.2 million in the third quarter of 2025.
What contributed to the increase in gross margins?
The increase in gross margins to 43.7% was primarily due to lower production costs following the closure of the Fremont manufacturing facility.
How did Lifeward's SEC filing impact its financial results?
The SEC filings provided greater transparency regarding financial performance and facilitated lifeward's funding strategy, allowing it to secure strategic loans.
How is Lifeward addressing operational efficiency?
Lifeward has implemented improved processes such as cost structure optimization, which has helped reduce cash burn by 16% year-over-year.
What is Lifeward’s future guidance for financial performance?
Lifeward expects revenues to be in the range of $24 to $26 million for the full year of 2025.
